Ono Pharmaceutical Co., Ltd. (OPHLY)
USD 4.15
(1.93%)
USD 4.15
(1.93%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 115.06 Billion JPY | -14.53% |
| 2023 | 134.62 Billion JPY | 73.64% |
| 2022 | 77.52 Billion JPY | -26.64% |
| 2021 | 105.68 Billion JPY | 0.25% |
| 2020 | 105.42 Billion JPY | 14.19% |
| 2019 | 92.32 Billion JPY | 15.97% |
| 2018 | 79.6 Billion JPY | -14.63% |
| 2017 | 93.25 Billion JPY | 45.26% |
| 2016 | 64.19 Billion JPY | 30.02% |
| 2015 | 49.37 Billion JPY | 45.37% |
| 2014 | 33.96 Billion JPY | 5.22% |
| 2013 | 32.28 Billion JPY | -8.92% |
| 2012 | 35.44 Billion JPY | 18.66% |
| 2011 | 29.87 Billion JPY | 10.15% |
| 2010 | 27.11 Billion JPY | -13.2% |
| 2009 | 31.23 Billion JPY | -33.64% |
| 2008 | 47.07 Billion JPY | -18.84% |
| 2007 | 58 Billion JPY | -4.61% |
| 2006 | 60.81 Billion JPY | 27.11% |
| 2005 | 47.84 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 101.04 Billion JPY | -10.29% |
| 2024 Q2 | 112.63 Billion JPY | 8.89% |
| 2024 Q1 | 103.43 Billion JPY | -23.17% |
| 2024 FY | 115.06 Billion JPY | -14.53% |
| 2024 Q4 | 115.06 Billion JPY | 13.87% |
| 2023 FY | 134.62 Billion JPY | 73.64% |
| 2023 Q4 | 134.62 Billion JPY | 30.41% |
| 2023 Q3 | 103.23 Billion JPY | 9.09% |
| 2023 Q2 | 94.63 Billion JPY | 9.42% |
| 2023 Q1 | 86.48 Billion JPY | 11.55% |
| 2022 Q1 | 92.73 Billion JPY | -12.25% |
| 2022 FY | 77.52 Billion JPY | -26.64% |
| 2022 Q4 | 77.52 Billion JPY | 5.15% |
| 2022 Q3 | 73.73 Billion JPY | -20.89% |
| 2022 Q2 | 93.2 Billion JPY | 0.5% |
| 2021 Q2 | 96.19 Billion JPY | 7.4% |
| 2021 Q1 | 89.57 Billion JPY | -15.03% |
| 2021 Q3 | 90.8 Billion JPY | -5.6% |
| 2021 FY | 105.68 Billion JPY | 0.25% |
| 2021 Q4 | 105.68 Billion JPY | 16.38% |
| 2020 Q3 | 86.19 Billion JPY | -1.13% |
| 2020 FY | 105.42 Billion JPY | 14.19% |
| 2020 Q1 | 86.35 Billion JPY | -6.46% |
| 2020 Q2 | 87.17 Billion JPY | 0.95% |
| 2020 Q4 | 105.42 Billion JPY | 22.31% |
| 2019 Q2 | 70.15 Billion JPY | -2.44% |
| 2019 Q1 | 71.91 Billion JPY | -9.67% |
| 2019 Q3 | 80.07 Billion JPY | 14.14% |
| 2019 FY | 92.32 Billion JPY | 15.97% |
| 2019 Q4 | 92.32 Billion JPY | 15.3% |
| 2018 Q4 | 79.6 Billion JPY | 16.29% |
| 2018 Q2 | 69.32 Billion JPY | 3.3% |
| 2018 Q1 | 67.11 Billion JPY | -28.03% |
| 2018 FY | 79.6 Billion JPY | -14.63% |
| 2018 Q3 | 68.45 Billion JPY | -1.25% |
| 2017 FY | 93.25 Billion JPY | 45.26% |
| 2017 Q4 | 93.25 Billion JPY | 25.91% |
| 2017 Q3 | 74.06 Billion JPY | 10.2% |
| 2017 Q2 | 67.2 Billion JPY | 7.33% |
| 2017 Q1 | 62.61 Billion JPY | -2.46% |
| 2016 Q4 | 64.19 Billion JPY | 33.59% |
| 2016 Q3 | 48.05 Billion JPY | 2.97% |
| 2016 Q1 | 49.78 Billion JPY | 0.83% |
| 2016 FY | 64.19 Billion JPY | 30.02% |
| 2016 Q2 | 46.66 Billion JPY | -6.27% |
| 2015 Q2 | 31.24 Billion JPY | -18.78% |
| 2015 FY | 49.37 Billion JPY | 45.37% |
| 2015 Q1 | 38.47 Billion JPY | 13.27% |
| 2015 Q4 | 49.37 Billion JPY | 18.24% |
| 2015 Q3 | 41.75 Billion JPY | 33.63% |
| 2014 Q3 | 38.75 Billion JPY | 20.41% |
| 2014 Q2 | 32.18 Billion JPY | -4.88% |
| 2014 FY | 33.96 Billion JPY | 5.22% |
| 2014 Q1 | 33.83 Billion JPY | 4.81% |
| 2014 Q4 | 33.96 Billion JPY | -12.35% |
| 2013 Q4 | 32.28 Billion JPY | 13.28% |
| 2013 Q1 | 35.58 Billion JPY | 0.38% |
| 2013 FY | 32.28 Billion JPY | -8.92% |
| 2013 Q3 | 28.49 Billion JPY | -1.15% |
| 2013 Q2 | 28.83 Billion JPY | -18.97% |
| 2012 Q3 | 30.35 Billion JPY | 1.22% |
| 2012 Q1 | 30.66 Billion JPY | 2.66% |
| 2012 Q4 | 35.44 Billion JPY | 16.76% |
| 2012 FY | 35.44 Billion JPY | 18.66% |
| 2012 Q2 | 29.99 Billion JPY | -2.2% |
| 2011 Q2 | 24.62 Billion JPY | -11.31% |
| 2011 FY | 29.87 Billion JPY | 10.15% |
| 2011 Q3 | 27.7 Billion JPY | 12.49% |
| 2011 Q4 | 29.87 Billion JPY | 7.82% |
| 2011 Q1 | 27.77 Billion JPY | 2.41% |
| 2010 Q2 | 30.02 Billion JPY | 0.0% |
| 2010 FY | 27.11 Billion JPY | -13.2% |
| 2010 Q4 | 27.11 Billion JPY | -1.15% |
| 2010 Q3 | 27.43 Billion JPY | -8.63% |
| 2009 Q4 | 31.23 Billion JPY | -16.09% |
| 2009 FY | 31.23 Billion JPY | -33.64% |
| 2009 Q3 | 37.22 Billion JPY | 0.0% |
| 2008 FY | 47.07 Billion JPY | -18.84% |
| 2007 FY | 58 Billion JPY | -4.61% |
| 2006 FY | 60.81 Billion JPY | 27.11% |
| 2005 FY | 47.84 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AstraZeneca PLC | 61.86 Billion USD | -85.989% |
| Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | -75.203% |
| CSPC Pharmaceutical Group Limited | 1.53 Billion USD | -7372.528% |
| Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | -170043.582% |
| Novartis AG | 53.19 Billion USD | -116.304% |
| PT Kalbe Farma Tbk. | 255.94 Million USD | -44856.933% |